Oncology

Space rocket moon explore
Biotech

Tumor-focused Parabilis raises $305M to 'upend status quo'

The biotech will harness the cash to advance FOG-001, recently named zolucatetide, towards a pivotal phase 3 trial in desmoid tumors.
Darren Incorvaia Jan 8, 2026 7:00am
Disco ball dancefloor

Amgen dances with Disco in $618M cancer target pact

Jan 7, 2026 10:15am
yellow road to bright light

Rakuten lights path to 2028 FDA filing with fresh $100M raise

Jan 7, 2026 9:43am
christmas presents

Gilead garners lipid package for cancer asset in $300M pact

Jan 6, 2026 7:00am
dollar sign with colored arrows in a maze

Pfizer Ventures gets behind Chinese biotech's $100M series A

Dec 5, 2025 4:20am
layoffs cut staff reduction workforce

Genetic medicines biotech halves team

Nov 20, 2025 10:15am
More News

Repare nails down XenoTherapeutics buyout

Nov 17, 2025 12:12pm

Bayer bails on Vividion tumor drug in early-stage clear-out

Nov 12, 2025 8:10am

Cullinan puts kibosh on 2 cancer assets amid autoimmune refocus

Nov 6, 2025 1:26pm

Novo drops oncology ambitions, early-stage MASH prospects

Nov 5, 2025 7:21am